Clinical Pharmacology of Eplontersen, the First Approved GalNAc‐Conjugated Antisense Oligonucleotide
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70276 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Rosie Z Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ionis Pharmaceuticals, Inc., Carlsbad, CA, USA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Oligonucleotides, Oligonucleotides, Antisense. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ionis Pharmaceuticals, Inc., AstraZeneca PLC, Ionis Pharmaceuticals.
Abstract (Originalsprache)
Eplontersen is a GalNAc‐conjugated antisense oligonucleotide (ASO) approved for the treatment of hereditary transthyretin‐mediated amyloidosis with polyneuropathy (ATTRv‐PN). GalNAc conjugation enables targeted hepatic delivery and improved potency compared with unconjugated ASOs. The clinical pharmacology of eplontersen was characterized by using in vitro studies and data from three Phase 1 studies in healthy participants and one pivotal Phase 3 study in patients with ATTRv‐PN. Following subcutaneous administration, eplontersen was rapidly absorbed and exhibited a biphasic pharmacokinetic (PK) profile with a terminal half‐life of approximately 3 weeks, supporting once‐monthly dosing. Eplontersen is highly plasma protein‑bound, distributes predominantly within the plasma compartment before receptor‑mediated tissue uptake, and is eliminated mainly via nuclease‑mediated metabolism, with minimal renal excretion of intact drug. Across integrated population PK/PKPD and exposure–response analyses at 45 mg Q4W, eplontersen exhibits predictable PK, robust PD, exposure‐independent efficacy within the achieved range, and no exposure‐dependent safety signals. Albeit some covariates were identified as statistically significant for population PK and population PKPD models, they were not considered clinically meaningful when taking into account the overall variability in PK, their minimal impact on TTR reduction, and the therapeutic window for eplontersen. These findings support that 45 mg Q4W is appropriate for patients with ATTRv‐PN without the need for dose modification. In vitro and model‐based analyses indicate low potential for clinically relevant plasma protein binding displacement and CYP‐ or transporter‐mediated drug–drug interactions, and demonstrate no clinically meaningful effects on the QT prolongation and a predominantly non‐neutralizing anti‐drug antibody profile without impact on efficacy or safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ionis Pharmaceuticals, Inc., Carlsbad, CA, USA.
- Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
ORCID-Profile: Xiang Gao
Förderung
- Ionis Pharmaceuticals, Inc.
- AstraZeneca PLC
- Ionis Pharmaceuticals
Zitieren
APA
Yu, R. Z., Diep, J. K., Gao, X., Arfvidsson, C., & Quartino, A. (2026). Clinical Pharmacology of Eplontersen, the First Approved GalNAc‐Conjugated Antisense Oligonucleotide. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70276
Vancouver
Yu RZ, Diep JK, Gao X, Arfvidsson C, Quartino A. Clinical Pharmacology of Eplontersen, the First Approved GalNAc‐Conjugated Antisense Oligonucleotide. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70276
BibTeX
@article{Yu2026,
author = {Yu, Rosie Z and Diep, John K and Gao, Xiang and Arfvidsson, Cecilia and Quartino, Angelica},
title = {Clinical Pharmacology of Eplontersen, the First Approved GalNAc‐Conjugated Antisense Oligonucleotide},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70276}
}
EUVIMED